Paratek Pharmaceuticals acquisition by Gurnet Point Capital and Novo Holdings

Paratek Pharmaceuticals (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, acquisition by Gurnet Point Capital, an investment fund that enables established healthcare and life science businesses to accelerate growth and achieve their long-term vision and Novo Holdings, an investment portfolio, with a long-term return perspective, for $462 million.